TABLE 1.

Characteristics of participants at entry into analysis by vaginal estrogen (VE) use in postmenopausal women

Characteristica	Overall
	No VE use	VE use
n	52901	896
Ageb, y	54.4 (3.9)	54.8 (4.0)
White, %	97	98
Age at menopause, y	49.6 (4.4)	49.0 (4.8)
Age at first birth, y	25.5 (12.4)	24.1 (12.6)
Body mass index, kg/m2	25.9 (5.2)	24.2 (4.1)
Height, inches	64.3 (3.3)	64.3 (2.3)
Smokingc
Never, %	43	49
Past, %	31	36
Current,%	27	15
Physical activity, MET-h/week	14.9 (21.3)	15.2 (17.4)
Alcohol intake, g/d	6.3 (10.8)	6.5 (9.7)
Bilateral oophorectomy, %	11	16
Hysterectomy, %	22	32
Parityc
Nulliparous, %	6	10
1 child, %	7	6
2–3 children, %	52	57
>3 children, %	36	27
History of past systemic hormone therapy use, %	19	47
Hypertension, %	33	28
Hypercholesterolemia, %	23	24
History of diabetes, %	12	11
History of benign breast disease, %	34	45
Parental history of early MI, %	14	14
Family history of cancer, %	19	21
Aspirin used, %	15	16

MET, metabolic equivalent task; VE, vaginal estrogen

^aValues are means(SD) or percentages and are standardized to the age distribution of the study population.

^bNot age adjusted

^cValues for polytomous variables do not add up to a 100 due to rounding

^dAt least 1 tablet per day